MedTrace Logo

HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b

NCT01342003 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 388

Last updated 2011-04-26

No results posted yet for this study

Summary

Sustained virological response (SVR) to antiviral therapy in patients with chronic hepatitis C genotype 1 according to subtype (1a vs.1b) has not been extensively investigated. This observational study was carried out on a large group of "naïve" HCV patients to evaluate difference, if any, between HCV genotype 1 subtype 1a and 1b on the response to treatment with peginterferon (Peg-IFN) plus ribavirin.

Conditions

  • Chronic Hepatitis C

Sponsors & Collaborators

  • Azienda Ospedaliera San Camillo Forlanini

    lead OTHER

Principal Investigators

  • Adriano M Pellicelli, MD · AO Scamilloforlanini Rome Italy

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2010-07-31
Completion
2010-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342003 on ClinicalTrials.gov